Ionis Pharmaceuticals (NASDAQ: IONS), known as Isis Pharmeceuticals until December 2015, is a publicly traded pharmaceutical company based in Carlsbad, California, United States. It has a single cholesterol-reducing drug in the market and several compounds in the drug pipeline including IONIS-HTTRx, the first intrathecally administered huntingtin-lowering drug for Huntington's disease; and nusinersen (IONIS-SMNRx), an intrathecally administered antisense oligonucleotide drug for spinal muscular atrophy.